Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)

Summary

Open-label study to evaluate the safety and tolerability of Sorafenib dose ramp-up (starting at a lower dose and then gradually increasing the dose) versus standard Sorafenib dosing in subjects with unresectable and/or metastatic hepatocellular carcinoma.

Timeline

Start

2010-12

Primary completion

2014-01

Completion

2014-03

Drugs

Indications